INVESTIGATION OF AN ORAL GLUCOCORTICOID-INDUCED OSTEOPOROSIS MOUSE MODEL
Main Article Content
Abstract
Objective: This study investigated biochemical parameters in osteoporosis mouse model induced by prolonged glucocorticoid administration.
Materials and methods: Mice were orally administered prednisone at doses of 5, 10, and 20 mg/kg/day continuously for 6 and 8 weeks. Biochemical parameters, including bone weight, ash weight, bone phosphorus and calcium content were evaluated. The model’s responsiveness (optimal dose/duration) to the anti-osteoporosis drug alendronate (5 mg/kg) was also assessed at 4 weeks post-prednisone treatment.
Results: Prednisone administration significantly reduced bone weight, ash weight, bone phosphorus and calcium content, with the most pronounced effects observed at the 20 mg/kg dose over 8 weeks. Alendronate treatment at dose 5mg/kg effectively increased these parameters, restoring bone health indicators.
Conclusion: The mouse model of prednisone-induced osteoporosis (20 mg/kg/day for 8 weeks) is suitable for evaluating the anti-osteoporosis efficacy of drugs and formulations in preclinical research.
Article Details
Keywords
Glucocorticoid-induced osteoporosis, alendronate, prednisone, phosphorus content in bone, calcium content in bone, …..
References
[2] Jee W, Yao W. Overview: Animal models of osteopenia and osteoporosis. The Journal of Musculoskeletal and Neuronal Interactions. 2001;1(3):193-207.
[3] Hà Quang Thanh. Mô phỏng mô hình gây loãng xương trên chuột nhắt trắng bằng glucocorticoid. [Luận văn Thạc sĩ ĐH KHTN TPHCM]. 2017: 26-27.
[4] NAFIQAD. Quyết định ban hành qui trình phân tích chuẩn xác định hàm lượng phốt pho bằng phương pháp quang phổ. Hà Nội. 2011.
[5] Bộ Khoa học và Công nghệ. Hướng dẫn quản lý hoạt động sử dụng động vật thí nghiệm. Thông tư số 04/2010/TT-BKHCN. 2010.
[6] Komori T. Animal models for osteoporosis. European Journal of Pharmacology. 2015; (759): 287-294. doi.org/10.1016/j.ejphar.2015.03.028.
[7] Canalis E. Glucocorticoid-induced osteoporosis:
Pathophysiology and therapy. Osteoporosis International. 2007; 8(10): 1319-1328. doi: 10.1007/s00198-007-0394-0.
[8] Malik K., Khaldoyanidi S, Frincke J. 5-Androstene 3beta,7beta,17beta-triol (beta-AET) slows thermal injury induced osteopenia in mice: relation to aging and osteoporosis. PLoS One. 2010; 5(10) e13566. doi: 10.1371/journal.pone.0013566.C.T.M. Duyen et al. / Vietnam Journal of Community Medicine, Vol. 67, No. 1, 132-137137
[9] Hara K., Akiyama Y, Ohkawa I., Tajima T. Effects of menatetrenone on prednisolone-induced bone loss in rats. Bone. 1993; 14 (6): 813-818. doi:10.1016/87563282(93)90309-x.
[10] Boskey L, Coleman R. Aging and bone. Journal of Dental Research. 2010; 89(12): 1333-1348. doi:10.1177/0022034510377791.
[11] Weinstein R. Inhibition of osteoblastogenesis and
promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Journal of Clinical Investigation. 1998; 102(2): 274-282. doi: 10.1172/JCI2799.
[12] Russell S. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporosis International. 2008: 19(6): 733-759. doi: 10.1007/s00198-007-0540-8.